CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed by insurance that disrupt treatments for patients.
Category: Eli Lilly and Company
-
Daily Pill May Work as Well as Ozempic for Weight Loss and Blood Sugar
Clinical results of a GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable drugs.
-
Patients Cut Off From Cheaper Obesity Drugs as FDA Halts Sales of Copycats
U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or suspend treatment for patients.
-
Trump’s Tariff Threat for Drug imports Poses Big Political Risks
Levies on Americans’ daily prescriptions and other medicines could raise costs, spur rationing and lead to shortages of critical drugs.
-
Eli Lilly Chief Says He Will Fight for the FDA, Challenging RFK Jr.’s Stance
The health care giant’s David Ricks defended the agency’s role in reviewing data and ensuring drug safety.
-
Jeff Bezos, Jay Powell, Serena Williams and More Will Speak at the DealBook Summit
The conference on Dec. 4 will bring together the biggest names in business, politics and culture.
-
What Drugmakers Did Not Tell Volunteers in Alzheimer’s Trials
Genetic tests showed that certain patients were predisposed to brain injuries if they took the drugs. That information remained secret.
-
U.S. Unveils Price Limits for 10 Costly or Common Medications
The Biden administration said it would have saved $6 billion had the new prices been in effect last year.
-
U.S. to Announce Prices for First Drugs Picked for Medicare Negotiations
The Biden administration said it would have saved $6 billion had the new prices been in effect last year.
-
New Drug Approved for Early Alzheimer’s
The drug, Kisunla, made by Eli Lilly, is the latest in a new class of treatments that could modestly slow cognitive decline in initial stages of the disease but also carry safety risks.
-
Advisory Panel of Experts Endorses F.D.A. Approval of New Alzheimer’s Drug
The modest benefits of the treatment, donanemab, made by Eli Lilly, outweigh the risks, the panel concluded unanimously.
-
U.S. Scrutiny of Chinese Company Could Disrupt U.S. Supply Chain for Key Drugs
Lawmakers raising national security concerns and seeking to disconnect a major Chinese firm from U.S. pharmaceutical interests have rattled the biotech industry. The firm is deeply involved in development and manufacturing of crucial therapies for cancer, cystic fibrosis, H.I.V. and other illnesses.